Expert Discusses Add-On Study Design for Ibrutinib as Treatment for Chronic Lymphocytic Leukemia


Lindsey Roeker, MD at assistant attending L1, Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses the study design and the sample demographics.

In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.

She discussed the study design and what the sample demographics were.

Related Videos
Image Credit: © Dragana Gordic -
small cell lung cancer treatment/Image Credit: © CraftyImago -
Close up hands of helping hands elderly home care. Mother and daughter. Mental health and elderly care concept - Image credit:  ipopba |
Ozempic, obesity, drug shortage, media portrayal | Image Credit: zimmytws -
Doctor using a stethoscope checking patient with examining, presenting results symptom and recommend treatment method, Healthcare and medical concept - Image credit: Ngampol |
Collaborative Care Team for Diabetes, Cardiovascular Disease | Image Credit: Production Perig -
Sleep Apenea C-PAP Machine | Image Credit: sbw19 -
lymphoma, OPC, ASCO 2024, hodgkin lymphoma
© 2024 MJH Life Sciences

All rights reserved.